Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254316957> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4254316957 endingPage "8229" @default.
- W4254316957 startingPage "8229" @default.
- W4254316957 abstract "8229 Background: Several randomized studies evaluating pegfilgrastim and filgrastim have shown no difference in ANC patterns in cycle 2 compared to cycle 1 of chemotherapy. We have observed an interesting ANC pattern in a phase II clinical study evaluating the safety and efficacy of accelerated dose- intensified neoadjuvant epirubicin with pegfilgrastim support in patients with breast cancer. Methods: Biopsy proven stage II/III breast cancer patients with primary tumors >2 cm and adequate hematologic, hepatic, renal, and cardiac function are eligible. Single agent epirubicin is given at 120 mg/m2 every 14 days for four cycles with pegfilgrastim support (6 mg subcutaneously once per cycle 24 hours following each treatment). Definitive surgery is performed 3–4 weeks after completion of chemotherapy. Postoperative therapy is given at the discretion of the investigator. Planned accrual is 30 patients. Results: To date 6 patients have been treated. All 6 have completed chemotherapy, and have undergone surgery. Two patients achieved a clinical complete response, 3 patients had a partial response, and 1 patient has stable disease. Grade 4 neutropenia (ANC<0.5 k/uL) was noted in all 6 patients following cycle 1 of chemotherapy. During cycles 2–4, no grade 4, and only 1 case of grade 3 neutropenia (ANC<0.5 k/uL) was observed in a total of 18 cycles of therapy given (Table). Conclusions: Accelerated, dose intensified epirubicin with pegfilgrastim is safe and appears efficacious as neoadjuvant therapy. The finding of grade 4 neutropenia in all patients after the first dose of epirubicin, but decreased myelosuppression with subsequent chemotherapy cycles suggests a “priming” effect of pegfilgrastim and warrants further study. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer" @default.
- W4254316957 created "2022-05-12" @default.
- W4254316957 creator A5001361894 @default.
- W4254316957 creator A5002450423 @default.
- W4254316957 creator A5016905895 @default.
- W4254316957 creator A5022309861 @default.
- W4254316957 creator A5027670902 @default.
- W4254316957 creator A5059599541 @default.
- W4254316957 creator A5069102893 @default.
- W4254316957 creator A5085460226 @default.
- W4254316957 date "2004-07-15" @default.
- W4254316957 modified "2023-10-16" @default.
- W4254316957 title "Absolute neutrophil count (ANC) pattern with accelerated dose-intensified epirubicin chemotherapy and pegfilgrastim support" @default.
- W4254316957 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.8229" @default.
- W4254316957 hasPublicationYear "2004" @default.
- W4254316957 type Work @default.
- W4254316957 citedByCount "0" @default.
- W4254316957 crossrefType "journal-article" @default.
- W4254316957 hasAuthorship W4254316957A5001361894 @default.
- W4254316957 hasAuthorship W4254316957A5002450423 @default.
- W4254316957 hasAuthorship W4254316957A5016905895 @default.
- W4254316957 hasAuthorship W4254316957A5022309861 @default.
- W4254316957 hasAuthorship W4254316957A5027670902 @default.
- W4254316957 hasAuthorship W4254316957A5059599541 @default.
- W4254316957 hasAuthorship W4254316957A5069102893 @default.
- W4254316957 hasAuthorship W4254316957A5085460226 @default.
- W4254316957 hasConcept C121608353 @default.
- W4254316957 hasConcept C126322002 @default.
- W4254316957 hasConcept C141071460 @default.
- W4254316957 hasConcept C143998085 @default.
- W4254316957 hasConcept C2776694085 @default.
- W4254316957 hasConcept C2776802502 @default.
- W4254316957 hasConcept C2777063308 @default.
- W4254316957 hasConcept C2778658803 @default.
- W4254316957 hasConcept C2778850193 @default.
- W4254316957 hasConcept C2779171977 @default.
- W4254316957 hasConcept C2780835546 @default.
- W4254316957 hasConcept C2781190966 @default.
- W4254316957 hasConcept C530470458 @default.
- W4254316957 hasConcept C71924100 @default.
- W4254316957 hasConcept C90924648 @default.
- W4254316957 hasConceptScore W4254316957C121608353 @default.
- W4254316957 hasConceptScore W4254316957C126322002 @default.
- W4254316957 hasConceptScore W4254316957C141071460 @default.
- W4254316957 hasConceptScore W4254316957C143998085 @default.
- W4254316957 hasConceptScore W4254316957C2776694085 @default.
- W4254316957 hasConceptScore W4254316957C2776802502 @default.
- W4254316957 hasConceptScore W4254316957C2777063308 @default.
- W4254316957 hasConceptScore W4254316957C2778658803 @default.
- W4254316957 hasConceptScore W4254316957C2778850193 @default.
- W4254316957 hasConceptScore W4254316957C2779171977 @default.
- W4254316957 hasConceptScore W4254316957C2780835546 @default.
- W4254316957 hasConceptScore W4254316957C2781190966 @default.
- W4254316957 hasConceptScore W4254316957C530470458 @default.
- W4254316957 hasConceptScore W4254316957C71924100 @default.
- W4254316957 hasConceptScore W4254316957C90924648 @default.
- W4254316957 hasIssue "14_suppl" @default.
- W4254316957 hasLocation W42543169571 @default.
- W4254316957 hasOpenAccess W4254316957 @default.
- W4254316957 hasPrimaryLocation W42543169571 @default.
- W4254316957 hasRelatedWork W146630477 @default.
- W4254316957 hasRelatedWork W1982206062 @default.
- W4254316957 hasRelatedWork W1995429954 @default.
- W4254316957 hasRelatedWork W2001753354 @default.
- W4254316957 hasRelatedWork W2031406601 @default.
- W4254316957 hasRelatedWork W2042759707 @default.
- W4254316957 hasRelatedWork W2053128632 @default.
- W4254316957 hasRelatedWork W2320262955 @default.
- W4254316957 hasRelatedWork W2944330928 @default.
- W4254316957 hasRelatedWork W2982282342 @default.
- W4254316957 hasVolume "22" @default.
- W4254316957 isParatext "false" @default.
- W4254316957 isRetracted "false" @default.
- W4254316957 workType "article" @default.